|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
178,600,000 |
Market
Cap: |
226.82(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.8901 - $1.85 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 7.4 |
Insider 3/6 Months : 8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
96,686 |
1,592,031 |
13,134,243 |
Total Buy Value |
$0 |
$136,327 |
$2,615,293 |
$22,822,494 |
Total People Bought |
0 |
1 |
4 |
8 |
Total Buy Transactions |
0 |
1 |
6 |
12 |
Total Shares Sold |
0 |
96,686 |
455,706 |
719,367 |
Total Sell Value |
$0 |
$136,327 |
$650,097 |
$1,021,712 |
Total People Sold |
0 |
1 |
6 |
6 |
Total Sell Transactions |
0 |
1 |
21 |
26 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kirk Randal J |
Director |
|
2022-03-25 |
4 |
OE |
$0.00 |
$0 |
I/I |
32,425 |
19,037,059 |
|
- |
|
Hassan Fred |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$56,499 |
D/D |
27,832 |
182,519 |
|
- |
|
Kindler Jeffrey B |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$69,000 |
D/D |
33,990 |
248,199 |
|
- |
|
Gupta Vinita D |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$56,499 |
D/D |
27,832 |
175,652 |
|
- |
|
Kirk Randal J |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$100,000 |
I/I |
49,261 |
19,004,634 |
|
- |
|
Frank Steven |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$49,999 |
D/D |
24,630 |
361,835 |
|
- |
|
Mitchell Dean J |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$56,499 |
D/D |
27,832 |
205,758 |
|
- |
|
Shapiro Robert B |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$62,999 |
D/D |
31,034 |
224,945 |
|
- |
|
Turley James S |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$62,500 |
D/D |
30,788 |
190,692 |
|
- |
|
Alvarez Cesar L |
Director |
|
2022-02-22 |
4 |
A |
$2.03 |
$62,500 |
D/D |
30,788 |
288,184 |
|
- |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2022-01-05 |
4 |
AS |
$3.59 |
$34,960 |
D/D |
(9,738) |
316,462 |
|
-61% |
|
Lehr Donald P. |
Chief Legal Officer |
|
2022-01-05 |
4 |
AS |
$3.59 |
$37,180 |
D/D |
(10,356) |
304,880 |
|
-61% |
|
Sabzevari Helen |
President and CEO |
|
2022-01-05 |
4 |
AS |
$3.59 |
$24,987 |
D/D |
(6,960) |
734,150 |
|
-61% |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,939 |
326,200 |
|
- |
|
Lehr Donald P. |
Chief Legal Officer |
|
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,939 |
315,236 |
|
- |
|
Sabzevari Helen |
President and CEO |
|
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,667 |
741,110 |
|
- |
|
Kirk Randal J |
Director |
|
2022-01-04 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,444 |
18,741,568 |
|
- |
|
Lehr Donald P. |
Chief Legal Officer |
|
2022-01-03 |
4 |
AS |
$3.67 |
$19,507 |
D/D |
(5,315) |
296,297 |
|
-69% |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2022-01-03 |
4 |
AS |
$3.67 |
$18,431 |
D/D |
(5,022) |
307,261 |
|
-69% |
|
Sabzevari Helen |
President and CEO |
|
2022-01-03 |
4 |
AS |
$3.67 |
$14,123 |
D/D |
(3,848) |
723,443 |
|
-69% |
|
Lehr Donald P. |
Chief Legal Officer |
|
2022-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,765 |
301,612 |
|
- |
|
Perez Jeffrey Thomas |
SVP, IP Affairs |
|
2022-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,765 |
312,283 |
|
- |
|
Sabzevari Helen |
President and CEO |
|
2022-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,765 |
727,291 |
|
- |
|
Thomasian Harry Jr. |
Chief Financial Officer |
|
2021-11-26 |
4 |
B |
$3.80 |
$100,831 |
D/D |
26,500 |
26,500 |
2.74 |
-45% |
|
Kirk Randal J |
Director |
|
2021-11-23 |
4 |
B |
$3.58 |
$1,741,079 |
I/I |
486,335 |
1,000,000 |
2.25 |
-35% |
|
689 Records found
|
|
Page 6 of 28 |
|
|